<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in <z:hpo ids='HP_0004808'>acute myeloblastic leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e>) and in therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, but rarely in <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> (ALLs) and <z:hpo ids='HP_0005506'>chronic myelogenous leukemias</z:hpo> (<z:mp ids='MP_0005481'>CMLs</z:mp>) </plain></SENT>
<SENT sid="1" pm="."><plain>Among 18 BCR-ABL+ <z:hpo ids='HP_0001909'>leukemias</z:hpo> presenting acquired <z:mp ids='MP_0004027'>trisomy</z:mp> of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> [BC] <z:mp ids='MP_0005481'>CML</z:mp> and one in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase <z:mp ids='MP_0005481'>CML</z:mp>) within the DNA-binding region of RUNX1 </plain></SENT>
<SENT sid="2" pm="."><plain>We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of <z:mp ids='MP_0004027'>trisomy</z:mp> 21 during disease progression </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC <z:mp ids='MP_0005481'>CMLs</z:mp> and, for the first time, 1 therapy-related BCR-ABL+ ALL </plain></SENT>
<SENT sid="5" pm="."><plain>Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion </plain></SENT>
<SENT sid="6" pm="."><plain>These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of <z:mp ids='MP_0005481'>CML</z:mp> and in BCR-ABL+ ALL </plain></SENT>
</text></document>